Background Our near-real-time safety monitoring of 16 adverse events (AEs) following
COVID-19 mRNA vaccination identified potential elevation in risk for six AEs following primary …

Importance In January 2023, the US Centers for Disease Control and Prevention and the
US Food and Drug Administration noted a safety concern for ischemic stroke among adults …

In January 2023, the United States Food and Drug Administration and the Centers for Disease
Control and Prevention noted a safety concern for ischemic stroke in adults 65 years of …

Background Long-term care residents were among the most vulnerable during the COVID-19
pandemic. We estimated vaccine effectiveness of mRNA COVID-19 vaccines in Medicare …

Background COVID-19 vaccines are authorized for use in children in the United States; real-world
assessment of vaccine effectiveness in children is needed. This study’s objective was …

Background Monovalent booster/additional doses of COVID-19 vaccines were first authorized
in August 2021 in the United States. We evaluated the real-world effectiveness of receipt …

Background The US FDA authorized the monovalent third primary series or booster doses
of COVID-19 mRNA vaccines in August 2021 for persons 18 years and older. Monitoring of …

Importance A recent study from the US Food and Drug Administration investigated the risk
of stroke following COVID to 19 bivalent and high to dose/adjuvanted influenza vaccines …

Real-world effectiveness of MRNA COVID-19 vaccines among elderly US nursing home
residents | Pharmacoepidemiology and Drug Safety; 31:483-483, 2022. | Web of Science …

In January 2023, the United States Food and Drug Administration and the Centers for Disease
Control and Prevention noted a safety concern for ischemic stroke in adults 65 years of …